trending Market Intelligence /marketintelligence/en/news-insights/trending/7_PEWkyqo_ulARJbEt4Ufw2 content esgSubNav
In This List

Strides Shasun receives US FDA approval for Parkinson's disease treatment

Blog

Insight Weekly: US inflation soars; real estate faces slowdown; megadeals drive tech M&A

Blog

Commercial Banking: June 22nd Edition

Blog

Understanding Loss Given Default A Review of Three Approaches

Blog

Insight Weekly: Path to net-zero; US manufacturing momentum; China's lithium M&A frenzy


Strides Shasun receives US FDA approval for Parkinson's disease treatment

Strides Shasun Ltd. said the U.S. Food and Drug Administration approved its amantadine hydrochloride capsules USP, 100 milligrams.

The drug, which the company will launch immediately, is used as treatment for Parkinson's disease and as pain reliever in the treatment of shingles.

The U.S. market for the product is about $25 million with three generic players, Strides Shasun said in a news release, citing IMS data.